Location:  Home » Biomedical Engineering » Beyond Anthrax: The Weaponization of Infectious Diseases    

Beyond Anthrax: The Weaponization of Infectious Diseases

Beyond Anthrax: The Weaponization of Infectious DiseasesCreators: Larry I. Lutwick, Suzanne M. Lutwick
Publisher: Humana Press
Category: Book

List Price: $149.00
Buy New: $85.32
as of 2/7/2012 19:48 PST details
You Save: $63.68 (43%)

In Stock
Buy

New (19) Used (15) from $85.32

Seller: Wiltonbooks

Languages: English (Unknown), English (Original Language), English (Published)
Media: Hardcover
Edition: 1
Pages: 390
Number Of Items: 1
Shipping Weight (lbs): 1.5
Dimensions (in): 9.3 x 6.1 x 0.9

ISBN: 1588294382
EAN: 9781588294388

Availability: Usually ships in 1-2 business days

Also Available In:

  • Kindle Edition - Beyond Anthrax: The Weaponization of Infectious Diseases
  • Paperback - Beyond Anthrax: The Weaponization of Infectious Diseases

Editorial Reviews:

Product Description
Biological warfare has, unfortunately, in the post 9/11 world become a significant topic of discussion in both the medical and lay presses. In the wake of the biological "letter bombs" containing anthrax spores, the possibility of biologic and/or toxic attacks on civilians in any part of the world became no longer a possibility. It is now part of common discussion and consciousness. This book presents the history of the topics and clinically relevant discussions on those high risk (Category A) diseases beyond anthrax as well as a number of infections and toxins at the Category B level. Importantly, in addition, the text includes sections on Public Health Infrastructure, Public Health Law, Surveillance, Mental Health Management and Media Role all of which relate to epidemics of any sort, not just intentional biological events. Beyond Anthrax: The Weaponization of Infectious Diseases is a product that should serve as a reference point for clinicians, epidemiologists and public health personnel to understand in practical detail many of the aspects of weapons of biowarfare as well as the appropriate responses to them.


In Stock
Buy